Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2014 May 9;20(8):1252–1257. doi: 10.1016/j.bbmt.2014.05.004

Figure 4. cGMP grade Ex-NK and FA-NK cells have different biodistribution in bone marrow and spleen.

Figure 4

(A) The number of human NK cells in bone marrow and spleen of mice given Ex-NK or FA-NK cells and cytokines as shown in Figure 1E. (B) The percent of proliferating (as evidenced by co-expression of Ki-67 on CD56+/CD3− cells) human NK cells 8 days after adoptive transfer of Ex-NK or FA-NK cells in bone marrow or spleen, respectively. (C) The proportion of CD57+ human NK cells 8 (left panel) and 15 (right panel) days after adoptive transfer of Ex-NK or FA-NK cells in bone marrow or spleen, respectively. Data are mean ± SE for all analyses (n=4). Where indicated, P values were determined using an unpaired t test to compare results for bone marrow and spleen within a treatment group.